{
    "nct_id": "NCT04250155",
    "official_title": "A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "Key General Inclusion Criteria\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Life expectancy >/= 12 weeks\n* Adequate hematologic and end-organ function\n* For participants receiving therapeutic anticoagulation: stable anticoagulant regimen\n* Negative serum pregnancy test for women of childbearing potential\n* Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n* Availability of representative tumor specimens\n\nKey General Exclusion Criteria\n\n* Pregnant or breastfeeding, or intending to become pregnant during the study\n* Significant cardiovascular disease\n* Current treatment with medications that prolong the QT interval\n* Known clinically significant liver disease\n* Poorly controlled Type 2 diabetes mellitus\n* Symptomatic, untreated, or actively progressing CNS metastases\n* History of leptomeningeal disease\n* History of malignancy other than disease under study within 3 years prior to screening\n* Active or history of autoimmune disease or immune deficiency\n* Active tuberculosis, hepatitis B, hepatitis C, or known/suspected Epstein Barr virus infection\n* Positive for HIV infection\n* Prior allogeneic stem cell or solid organ transplantation\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}